Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.
Webb MJ, Kottke T, Kendall BL, Swanson J, Uzendu C, Tonne J, Thompson J, Metko M, Moore M, Borad M, Roberts L, Diaz RM, Olin M, Borgatti A, Vile R. Webb MJ, et al. Among authors: moore m. Mol Ther Oncolytics. 2023 May 22;29:129-142. doi: 10.1016/j.omto.2023.05.006. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37313455 Free PMC article.
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG. Evgin L, et al. Among authors: moore m. Sci Transl Med. 2022 Apr 13;14(640):eabn2231. doi: 10.1126/scitranslmed.abn2231. Epub 2022 Apr 13. Sci Transl Med. 2022. PMID: 35417192 Free PMC article.
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. Smith KER, et al. Among authors: moore m. Front Immunol. 2023 Oct 31;14:1279387. doi: 10.3389/fimmu.2023.1279387. eCollection 2023. Front Immunol. 2023. PMID: 38022659 Free PMC article. Clinical Trial.
Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy.
Vile R, Webb M, van Vloten J, Evgin L, Sangsuwannukul T, Kendall B, Tonne J, Thompson J, Metko M, Moore M, Yerovi MC, McNiven M, Monga S, Borad M, Roberts L. Vile R, et al. Among authors: moore m. Res Sq [Preprint]. 2023 Nov 20:rs.3.rs-3576281. doi: 10.21203/rs.3.rs-3576281/v1. Res Sq. 2023. Update in: Nat Commun. 2024 Jun 27;15(1):5442. doi: 10.1038/s41467-024-49286-x PMID: 38045348 Free PMC article. Updated. Preprint.
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
Webb MJ, Sangsuwannukul T, van Vloten J, Evgin L, Kendall B, Tonne J, Thompson J, Metko M, Moore M, Chiriboga Yerovi MP, Olin M, Borgatti A, McNiven M, Monga SPS, Borad MJ, Melcher A, Roberts LR, Vile R. Webb MJ, et al. Among authors: moore m. Nat Commun. 2024 Jun 27;15(1):5442. doi: 10.1038/s41467-024-49286-x. Nat Commun. 2024. PMID: 38937436 Free PMC article.
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.
Vile R, Pulido J, Chen A, Kendall B, Tonne J, Metko M, Thompson J, Sangsuwannukul T, Yerovi MC, Diaz R, Webb M, Huff A, Moore M, Schuelke M, Irshad S, Appleton E, Melcher A. Vile R, et al. Among authors: moore m. Res Sq [Preprint]. 2024 Nov 15:rs.3.rs-5411393. doi: 10.21203/rs.3.rs-5411393/v1. Res Sq. 2024. PMID: 39606441 Free PMC article. Preprint.
7,513 results